Chronic Pain Market Report 2025

The chronic pain market size has grown strongly in recent years. It will grow from $78.79 billion in 2024 to $84.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to injury and trauma, surgical procedures, inflammatory conditions, nerve damage and neuropathy, lack of effective treatments.

The chronic pain market size is expected to see strong growth in the next few years. It will grow to $117.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to aging population, telemedicine expansion, public health awareness, genetic research and precision medicine, psychosocial stressors. Major trends in the forecast period include integration of wearable devices, pain education and support groups, holistic pain management, non-opioid pain management, regenerative medicine for pain.

The increasing prevalence of chronic pain patients is anticipated to boost the growth of the chronic pain market. Chronic pain patients are those who experience ongoing or long-lasting pain that extends beyond the typical healing process, generally lasting over three months. The high number of chronic pain patients propels market growth, as the rising demand for effective pain management solutions, including pharmaceuticals and medical devices, creates opportunities for innovation and development within the industry. For instance, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that an estimated 4 million Australians (16% of the population) were living with back problems in 2022. By 2023, back issues had become the third leading cause of disease burden, accounting for 4.3% of the country’s total disease burden. Additionally, in February 2024, a report from the Institute for Health Metrics and Evaluation, a US-based public health agency and research institute, projected that global cases of neck pain are expected to reach 269 million by 2050 (with a range of 219 to 322 million), reflecting a 32.5% increase (between 23.9% and 42.3%) compared to 2020. Thus, the prevalence of chronic pain patients is driving the growth of the chronic pain market.

The aging demographic, characterized by a larger proportion of elderly individuals in society, contributes significantly to the expansion of the chronic pain market. As the population ages, there's an augmented reliance on chronic pain management strategies to address age-related conditions, promoting overall physical and mental well-being. According to the World Health Organization's projections from October 2022, the global population aged 60 years and older is set to double by 2050, reaching 2.1 billion. This trend suggests a continued upsurge in demand for chronic pain management solutions to cater to the needs of the aging population, thereby driving market growth.

Companies in the chronic pain market are actively concentrating on novel and user-friendly nerve stimulation devices employing electrical impulses to alleviate pain. These portable devices provide non-invasive pain management options. For instance, Abbott Laboratories, a prominent US healthcare firm, introduced Eterna in December 2022. Eterna stands as the most compact implantable and rechargeable spinal cord stimulation (SCS) system available. Utilizing Abbott's unique low-dose BurstDR stimulation, it demonstrated a 23% greater pain reduction compared to traditional waveform technologies, supported by extensive clinical evidence (1A evidence).

Major players in the chronic pain market are embracing a strategic partnership approach to introduce a shared savings program aimed at managing chronic pain effectively. This collaborative strategy involves leveraging the combined strengths and resources of involved companies. In August 2023, MOBĒ, a US-based digital health innovator, joined forces with Override Health, a healthcare company in the US. Their shared objective is to address chronic pain management through a program that amalgamates their respective expertise. MOBĒ employs healthcare data analytics for high-touch, one-to-one health coaching and medication management, while Override Health offers virtual interdisciplinary care, neuroplasticity-centered coaching, and peer support to assist individuals navigating the complexities of chronic pain.

In October 2024, Stryker Corporation, a medical technology company based in the US, acquired Vertos Medical Inc. for an undisclosed sum. This acquisition aims to enhance unique, non-surgical solutions for interventionalists treating chronic lower back pain and to expand their presence in ambulatory surgery centers. Vertos Medical Inc. is a US-based manufacturer specializing in devices for chronic pain management, with a specific focus on treatments for chronic lower back pain resulting from lumbar spinal stenosis.

Major companies operating in the chronic pain market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Mitsubishi Chemical Group Corporation, GlaxoSmithKline plc., Eli Lilly and Company, AstraZeneca plc., Becton, Dickinson, and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Endo International plc., Noven Pharmaceuticals Inc., Anika Therapeutics Inc., Collegium Pharmaceutical Inc., Heron Therapeutics Inc., Paradigm Biopharmaceuticals Ltd., Braeburn Inc., Taiwan Liposome Company Ltd., Axial Healthcare, AcelRx Pharmaceuticals Inc., Centrexion Therapeutics Corp., Vertanical GmbH, IKI Health Group, Tonix Pharmaceuticals Inc., Paperplane Therapeutics.

North America was the largest region in the chronic pain market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic pain is characterized by persistent or long-lasting discomfort that extends beyond the normal healing period following an injury or illness. It can have diverse origins, including injuries, underlying medical conditions, nerve damage, inflammation, musculoskeletal disorders, and specific diseases such as arthritis, fibromyalgia, or neuropathy.

The primary products utilized for managing chronic pain are drugs and devices. Drugs refer to substances used for diagnosing, preventing, or treating diseases or medical conditions. Commonly employed medications for chronic pain include opioids and non-steroidal anti-inflammatory drugs (NSAIDs), aimed at alleviating pain symptoms and addressing underlying causes. These drugs are utilized for various indications, including neuropathic pain, arthritis pain, chronic back pain, cancer pain, migraines, fibromyalgia, and others. End-users of these products include hospitals, clinics, and research organizations.

The chronic pain market research report is one of a series of new reports that provides chronic pain market statistics, including chronic pain industry global market size, regional shares, competitors with a chronic pain market share, detailed chronic pain market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pain industry. This chronic pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic pain market consists of sales of opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other analgesics that are used to manage chronic pain. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.